NCI Definition: Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis. [1]

Core binding factor acute myeloid leukemias most frequently harbor alterations in NRAS, KIT, ASXL1, TET2, and FLT3 [2].

Most Commonly Altered Genes in Core Binding Factor Acute Myeloid Leukemia

NRAS Mutation, KIT Mutation, KIT Exon 17 Mutation, ASXL1fs, and NRAS Exon 2 Mutation are the most common alterations in core binding factor acute myeloid leukemia [2].

Top Alterations in Core Binding Factor Acute Myeloid Leukemia

Significant Genes in Core Binding Factor Acute Myeloid Leukemia


MYH11 +



Disease Details

Acute Myeloid Leukemia with Recurrent Genetic Abnormalities
Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 and Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.